Top

Current Hepatology Reports

Published in:

01-12-2020 | Fatty Liver | Fatty Liver Disease (D Halegoua-DeMarzio, Section Editor)

Alcohol Consumption in Non-Alcoholic Fatty Liver Disease: Safety and Disease Overlap

Author: Sheela S. Reddy

Published in: Current Hepatology Reports | Issue 4/2020

Abstract

Purpose of Review

As the non-alcoholic fatty liver disease (NAFLD) epidemic continues to grow, more patients will be seeking advice on the safety of low to moderate alcohol use in the setting of underlying liver disease. Data suggests a beneficial effect in the general population, but whether this can be extended to the NAFLD population remains unclear. The purpose of this review is to summarize pertinent data in order to help guide medical decision-making and patient counseling.

Recent Findings

Newer data suggests light to moderate alcohol use in patients with NAFLD can improve all-cause mortality, as well as cardiovascular risk. However, dose-dependent detrimental liver-related effects have also been noted.

Summary

The data is both limited and mixed in terms of the safety and potential benefit of low to moderate alcohol use in underlying NAFLD. More research is needed in specific NAFLD sub-groups in order to better counsel individual patients.

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease- meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84. https://doi.org/10.1002/hep.28431.CrossRefPubMed

• Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of nonalcoholic fatty liver disease. Hepatology. 2020. https://doi.org/10.1002/hep.31173Important study highlighting the increasing global burden of NAFLD.

Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577–86. https://doi.org/10.1002/hep.28785.CrossRefPubMed

Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, et al. Epidemiology of chronic liver disease in the USA in the past three decades. Gut. 2020;69:564–8. https://doi.org/10.1136/gutjnl-2019-318813.CrossRefPubMed

Younossi AM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793–801. https://doi.org/10.1016/j.jhep.2019.06.021.CrossRefPubMed

Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, Gores GJ, et al. Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease. Hepatology. 2020;71:907–16. https://doi.org/10.1002/hep.30858.

Kanwal F, Kramer JR, Li L, Dai J, Natarajan Y, Yu X, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology. 2020;71:808–19. https://doi.org/10.1002/hep.31014.CrossRefPubMed

Eslam M, Sanyal AJ, George J. International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312.CrossRefPubMed

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–57. https://doi.org/10.1002/hep.29367.CrossRefPubMed

10.

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016:64:1388–1402. Doi:https://doi.org/10.1016/j.jhep.2015.11.004.

11.

Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw Open. 2019;2:e1912565. https://doi.org/10.1001/jamanetworkopen.2019.12565.CrossRefPubMedPubMedCentral

12.

Lackner C, Tiniakos D. Fibrosis and alcohol-related liver disease. J Hepatol. 2019;70:294–304. https://doi.org/10.1016/j.jhep.2018.12.003.CrossRefPubMed

13.

Anstee QM, Seth D, Day CP. Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease. Gastroenterology. 2016;150:1728–44.e7. https://doi.org/10.1053/j.gastro.2016.01.037.CrossRefPubMed

14.

Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histologic severity of non-alcoholic fatty liver disease. Hepatology. 2011;53:1883–94. https://doi.org/10.1002/hep.24283.CrossRefPubMed

15.

Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet. 2010;42:21–3. https://doi.org/10.1038/ng.488.

16.

•• Ajmera VH, Terrault NA, Harrison SA. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. Hepatology. 2017;65:2090–9. https://doi.org/10.1002/hep.29055Critical review highlighting data and methodological issues with pertinent data on this topic.CrossRefPubMedPubMedCentral

17.

Trepo E, Guyot E, Ganne-Carrie N, Degre D, Gustot T, Franchimont D, et al. PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis. Hepatology. 2012;55:1307–8. https://doi.org/10.1002/hep.25518.CrossRefPubMed

18.

Liu YL, Patman GL, Leathart JB, Piguet A-C, Burt AD, Dufour J-F, et al. Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol. 2014;61:75–81. https://doi.org/10.1016/j.jhep.2014.02.030.CrossRefPubMed

19.

Liu YL, Reeves HL, Burt AD, Tiniako D, McPherson S, Leathart JB, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014:5:4309. Published 2014 Jun 30. https://doi.org/10.1038/ncomms5309.

20.

Stickel F, Moreno C, Hampe J, Morgan MY. The genetics of alcohol dependence and alcohol-related liver disease. J Hepatol. 2017;66:195–211. https://doi.org/10.1016/j.jhep.2016.08.011.

21.

Thun MJ, Peto R, Lopez AD, Monaco JH, Henley SJ, Heath CW, et al. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med. 1997;337:1705–14. https://doi.org/10.1056/NEJM199712113372401.CrossRefPubMed

22.

Di Castelnuovo A, Costanzo S, Bagnardi V, Donati MB, Iacoviello L, de Gaetano G. Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies. Arch Intern Med. 2006;166:2437–45. https://doi.org/10.1001/archinte.166.22.2437.CrossRefPubMed

23.

Xi B, Veeranki SP, Zhao M, Ma C, Yan Y, Mi J. Relationship of alcohol consumption to all-cause, cardiovascular, and cancer-related mortality in U.S. adults. J Am Coll Cardiol. 2017;70:913–22. https://doi.org/10.1016/j.jacc.2017.06.054.

24.

Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ. 2011;342:d671. https://doi.org/10.1136/bmj.d671.

25.

Bell S, Daskalopoulou M, Rapsomaniki E, George J, Britton A, Bobak M, et al. Association between clinically recorded alcohol consumption and initial presentation of 12 cardiovascular diseases: population based cohort study using linked health records. BMJ. 2017;356:j909. https://doi.org/10.1136/bmj.j909.

26.

Kerr WC, Ye Y, Williams E, Lui CK, Greenfield TK, Lown AE. Lifetime alcohol use patterns and risk of diabetes onset in the National Alcohol Survery. Alcohol Clin Exp Res. 2019;43:262–9. https://doi.org/10.1111/acer.13924.

27.

Li X, Yu F, Zhou Y, He J. Association between alcohol consumption and the risk of incident type 2 diabetes: a systematic review and dose-response meta-analysis. Am J Clin Nutr. 2016;103:818–29. https://doi.org/10.3945/ajcn.115.114389.

28.

Koppes LJ, Dekker JM, Hendriks HF, Bouter LM, Heine RJ. Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observational studies. Diabetes Care. 2005;28:719–25. https://doi.org/10.2337/diacare.28.3.719.

29.

Blomster JI, Zoungas S, Chalmers J, Li Q, Chow CK, Woodward M, et al. The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes. Diabetes Care. 2014;37:1353–9. https://doi.org/10.2337/dc13-2727.CrossRefPubMed

30.

Manolis TA, Manolis AA, Manolis AS. Cardiovascular effects of alcohol: a double-edged sword/how to remain at the nadir point of the j-curve. Alcohol. 2019;76:117–29. https://doi.org/10.1016/j.alcohol.2018.08.011.CrossRefPubMed

31.

O’Keefe JH, Bybee KA, Lavie CJ. Alcohol and cardiovascular health: the razor-sharp double-edged sword. J Am Coll Cardiol. 2007;50:1009–14. https://doi.org/10.1016/j.jacc.2007.04.089.CrossRefPubMed

32.

Mukamal KJ, Chen CM, Rao SR, Breslow RA. Alcohol consumption and cardiovascular mortality among U.S. adults, 1987 to 2002. J Am Coll Cardiol. 2010;55:1328–35. https://doi.org/10.1016/j.jacc.2009.10.056.CrossRefPubMed

33.

Bagnard V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2015;112:580–93. https://doi.org/10.1038/bjc.2014.579.CrossRef

34.

Choi YJ, Myung SK, Lee JH. Light alcohol drinking and risk of cancer: a meta-analysis of cohort studies. Cancer Res Treat. 2018;50:474–87. https://doi.org/10.4143/crt.2017.094.CrossRefPubMed

35.

Rock CL, Thomson C, Gansler T, Gapstur SM, McCullough ML, Patel AV. American Cancer Society guideline for diet and physical activity for cancer prevention. CA Cancer J Clin. 2020. https://doi.org/10.3322/caac.21591.

36.

Petroni ML, Brodosi L, Marchignoli F, Musio A, Marchesini G. Moderate alcohol intake in non-alcoholic fatty liver disease: to drink or not to drink? Nutrients. 2019;11:3048. https://doi.org/10.3390/nu11123048.

37.

Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, et al. Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population. Am J Gastroenterol. 2009;104:2189–95. https://doi.org/10.1038/ajg.2009.361.CrossRefPubMed

38.

Hiramine Y, Imamura Y, Uto H, Koriyama C, Horiuchi M, Oketani M, et al. Alcohol drinking patterns and the risk of fatty liver in Japanese men. J Gastroenterol. 2011;46:519–28. https://doi.org/10.1007/s00535-010-0336-z.

39.

Moriya A, Iwasaki Y, Ohguchi S, Kayashima E, Mitsumune T, Taniguchi H, et al. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;33:378–88. https://doi.org/10.1111/j.1365-2036.2010.04520.x.CrossRefPubMed

40.

Sookoian S, Castano GO, Pirola CJ. Modest alcohol consumption decreased the risk of non-alcoholic fatty liver disease: a meta-analysis of 43,175 individuals. Gut. 2014;63:530–2. https://doi.org/10.1136/gutjnl-2013-305718.CrossRefPubMed

41.

Cao G, Yi T, Liu Q, Wang M, Tang S. Alcohol consumption and risk of fatty liver disease: a meta-analysis. PeerJ. 2016;4:e2633. https://doi.org/10.7717/peerj.2633.CrossRefPubMedPubMedCentral

42.

Hashimoto Y, Hamaguchi M, Kojima T, Ohshima Y, Ohbora A, Kato T, et al. The modest alcohol consumption reduces the incidence of fatty liver in men: a population-based large-scale cohort study. J Gastroenterol Hepatol. 2015;30:546–52. https://doi.org/10.1111/jgh.12786.CrossRefPubMed

43.

Moriya A, Iwasaki Y, Ohguchi S, Kayashima E, Mitsumune T, Taniguchi H, et al. Roles of alcohol consumption in fatty liver: a longitudinal study. J Hepatol. 2015;62:921–7. https://doi.org/10.1016/j.jhep.2014.11.025.CrossRefPubMed

44.

Roerecke M, Nanau R, Rehm J, Neuman M. Ethnicity matters: a systemic review and meta-analysis of the non-linear relationship between alcohol consumption and prevalence and incidence of hepatic steatosis. EbioMedicine. 2016;8:317–30. https://doi.org/10.1016/j.ebiom.2016.04.023.CrossRefPubMedPubMedCentral

45.

Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008;49:608–12. https://doi.org/10.1016/j.jhep.2008.06.018.CrossRefPubMed

46.

Younossi ZM, Stepanova M, Ong J, Yilmaz Y, Duseja A, Eguchi Y, et al. Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic fatty and alcohol-related fatty liver disease. Clin Gastroenterol Hepatol. 2019;17:1625–33. https://doi.org/10.1016/j.cgh.2018.11.033.

47.

•• Hajifathalian K, Sagvand BT, McCullough AJ. Effect of alcohol consumption on survival in nonalcoholic fatty liver disease: a national prospective cohort study. Hepatology. 2019;70:511–21. https://doi.org/10.1002/hep.30226Important study highlighting improved survival in NAFLD patients with low to moderate alcohol intake.CrossRefPubMed

48.

•• Aberg F, Puuka P, Salomaa V, Mannisto S, Lundqvist A, Valsta L, et al. Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts. Hepatology. 2020;71:835–48. https://doi.org/10.1002/hep.30864Important study highlighting liver related outcomes in NAFLD patients with low to moderate alcohol intake.CrossRefPubMed

49.

Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow up. Hepatology. 2015;61:1547–54. https://doi.org/10.1002/hep.27368.CrossRefPubMed

50.

Dunn W, Sanyal AJ, Brunt EM, Unalp-Arida A, Donohue M, McCullough AJ, et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol. 2012;57:384–91. https://doi.org/10.1016/j.jhep.2012.03.024.CrossRefPubMedPubMedCentral

51.

Kwon HK, Greenson JK, Conjeevaram HS. Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease. Liver Int. 2014;34:129–35. https://doi.org/10.1111/liv.12230.CrossRefPubMed

52.

Hagstrom H, Nasr P, Ekstedt M, Kechagias S, Onnerhag K, Nilsson E, et al. Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2017;52:159–65. https://doi.org/10.1080/00365521.2016.1239759.CrossRefPubMed

53.

Mitchell T, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Ching H, et al. Type and pattern of alcohol consumption is associated with liver fibrosis in patients with non-alcoholic fatty liver disease. Am J Gastroenterol. 2018;113:1484–93. https://doi.org/10.1038/s41395-018-0133-5.CrossRefPubMed

54.

Ajmera V, Belt P, Wilson LA, Gill RM, Loomba R, Kleiner DE, et al. Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis. Clin Gastroenterol Hepatol. 2018;16:1511–20. https://doi.org/10.1016/j.cgh.2018.01.026.CrossRefPubMedPubMedCentral

55.

Chang T, Cho YK, Kim Y, Sung E, Ahn J, Jung HS, et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. Hepatology. 2019;69:64–75. https://doi.org/10.1002/hep.30170.CrossRefPubMed

56.

Sinn DH, Gwak GY, Cho J, Son HJ, Paik YH, Choi MS, et al. Modest alcohol consumption and carotid plaques or carotid artery stenosis in men with non-alcoholic fatty liver disease. Atherosclerosis. 2014;234:270–5. https://doi.org/10.1016/j.atherosclerosis.2014.03.001.CrossRefPubMed

57.

VanWagner LB, Ning H, Allen NB, Ajmera V, Lewis CE, Carr JJ, et al. Alcohol use and cardiovascular disease risk in patients with nonalcoholic fatty liver disease. Gastroenterology. 2017;153:1260–72. https://doi.org/10.1053/j.gastro.2017.08.012.CrossRefPubMedPubMedCentral

58.

Xu L, Xie J, Chen S, Chen Y, Yang H, Miao M, et al. Light-to-moderate alcohol consumption is associated with increased risk of type 2 diabetes in individuals with nonalcoholic fatty liver disease: a nine-year cohort study. Am J Gastroenterol. 2020;115:876–84. https://doi.org/10.14309/ajg.0000000000000607.CrossRefPubMed

59.

Patel PJ, Smith D, Connor JP, Horsfall LU, Hayward KL, Hossain F, et al. Alcohol consumption in diabetic patients with nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol. 2017;7927685. https://doi.org/10.1155/2017/7927685.

60.

Young S, Tariq R, Provenza J, Satapathy SK, Faisal K, Choudhry A, et al. Prevalence and profile of nonalcoholic fatty liver disease in lean adults: systemic review and meta-analysis. Hepatol Commun. 2020;4:953–72. https://doi.org/10.1002/hep4.1519.CrossRefPubMedPubMedCentral

61.

Leung JC, Loong TC, Wei JL, Wong GC, Chan AW, Choi PC, et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology. 2017;65:54–64. https://doi.org/10.1002/hep.28697.CrossRefPubMed

62.

Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stal P, Hultcrantz, et al. Risk for development of sever liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow up study. Hepatol Commun. 2018;2:48–57. https://doi.org/10.1002/hep4.1124.CrossRefPubMed

63.

Metcalf PA, Scragg RK, Jackson R. Light to moderate alcohol consumption is protective for type 2 diabetes mellitus in normal weight and overweight individuals but not the obese. J Obes. 2014;634587. https://doi.org/10.1155/2014/634587.

64.

• Chang Y, Ryu S, Kim Y, Cho YK, Sung E, Kim H, et al. Low levels of alcohol consumption, obesity, and development of fatty liver with and without evidence of advanced fibrosis. Hepatology. 2020;71:861–73. https://doi.org/10.1002/hep.30867Important study that sets the stage to further investigate the interplay between low to moderate alcohol use, obesity, and NAFLD.CrossRefPubMed

65.

Lau K, Baumeister E, Lieb W, Meffert PJ, Lerch MM, Mayerle J, et al. The combined effects of alcohol consumption and body mass index on hepatic steatosis in a general population sample of European men and women. Aliment Pharmacol Ther. 2015;41:467–76. https://doi.org/10.1111/apt.13067.CrossRefPubMed

66.

Aberg F, Helenius-Hietala J, Puuka P, Farkkila M, Jula A. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology. 2018;67:2141–9. https://doi.org/10.1002/hep.29631.CrossRefPubMed

67.

Long MT, Massaro JM, Hoffman U, Benjamin EJ, Naimi TJ. Alcohol use is associated with hepatic steatosis among persons with presumed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2020;18:1831–41.e5. https://doi.org/10.1016/j.cgh.2019.11.022.CrossRefPubMed

68.

Haseeb S, Alexander B, Baranchuk A. Wine and cardiovascular health: a comprehensive review. Circulation. 2017;136:1434–48. https://doi.org/10.1161/CIRCULATIONAHA.117.030387.CrossRefPubMed

69.

Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology. 2008;47:1947–54. https://doi.org/10.1002/hep.22292.CrossRefPubMedPubMedCentral

70.

Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70:1457–69. https://doi.org/10.1002/hep.30626.CrossRefPubMedPubMedCentral

71.

Stockwell T, Zhao J, Macdonald S. Who under-reports their alcohol consumption in telephone surveys and by how much? An application of the “yesterday method” in a national Canadian substance use survey. Addiction. 2014;109:1657–66. https://doi.org/10.1111/add.12609.CrossRefPubMed

72.

Stockwell T, Zhao J, Greenfield T, Li J, Livingston M, Meng Y. Estimating under- and over-reporting of drinking in national surveys of alcohol consumption: identification of consistent biases across four English-speaking countries. Addiction. 2016;111:1203–13. https://doi.org/10.1111/add.13373.CrossRefPubMedPubMedCentral

73.

• National Institute on Alcohol Abuse and Alcoholism. “What is a standard drink?” (https://www.niaaa.nih.gov/what-standard-drink) Accessed 4 July 2020. Important to know definition of standard drink in order to better counsel patients.

74.

Kerr WC, Stockwell T. Understanding standard drinks and drinking guidelines. Drug Alcohol Rev. 2012;31:200–5. https://doi.org/10.1111/j.1465-3362.2011.00374.x.CrossRefPubMed

75.

Johansen D, Friis K, Skovenborg, Gronbaek M. Food buying habits of people who buy wine or beer: cross-sectional study. BMJ. 2006;332:519–22. https://doi.org/10.1136/bmj.38694.568981.80.CrossRefPubMedPubMedCentral

Title: Alcohol Consumption in Non-Alcoholic Fatty Liver Disease: Safety and Disease Overlap
Author: Sheela S. Reddy
Publication date: 01-12-2020
Publisher: Springer US
Keyword: Fatty Liver
Published in: Current Hepatology Reports / Issue 4/2020
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-020-00542-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2020

Racial and Sex Disparities in Hepatocellular Carcinoma in the USA

Role of Nucleic Acid Polymers and Entry Inhibitors in Functional Cure Strategies for HBV

Role of Immunomodulators in Functional Cure Strategies for HBV

Current and Emerging Treatments for Non-alcoholic Steatohepatitis

The Role of Gut Microbiome-Targeted Therapy in Nonalcoholic Fatty Liver Disease

The Role of RNA Interference in Functional Cure Strategies for Chronic Hepatitis B

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage